¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Medicamento con receta

Vanzacaftor, tezacaftor, and deutivacaftor

Clase de medicamento: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

La «clase farmacológica establecida» de la FDA: el grupo de medicamentos que actúan de forma parecida. Se muestra en inglés, como la publica la FDA.

Datos oficiales de la FDA, no son consejos

Todo lo que aparece aquí viene de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA): la etiqueta del medicamento, el directorio NDC, Drugs@FDA, los informes de retiros y la lista de escasez. Cada dato indica su fuente y su fecha.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

En una emergencia, llame al 911. Si alguien pudo haber tomado demasiado de un medicamento, llame a la Línea de Ayuda para Envenenamientos (Poison Help): 1‑800‑222‑1222.

Vanzacaftor, tezacaftor, and deutivacaftor: datos clave

Clase de medicamento
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Se usa para
En inglés, según la etiqueta: ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on … (fuente)
Con receta o sin receta
Con receta (Rx)
Hay genérico
La FDA no indica genérico
Último retiro de la FDA
Ninguno registrado

Fuentes: etiqueta de la FDA (26 de agosto de 2026); directorio NDC de la FDA (13 de noviembre de 2026); informes de retiros de la FDA (10 de noviembre de 2026). No es un consejo médico.

Respuestas rápidas

¿Para qué se usa Vanzacaftor, tezacaftor, and deutivacaftor?
La etiqueta aprobada por la FDA (Alyftrek, Vertex Pharmaceuticals Incorporated, 26 de agosto de 2026) dice, en inglés: “ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 5 ) or results in production of CFTR protein […]. …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Cuáles son los efectos secundarios de Vanzacaftor, tezacaftor, and deutivacaftor?
La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Alyftrek, Vertex Pharmaceuticals Incorporated, 26 de agosto de 2026) comienza así, en inglés: «The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Drug-Induced Liver Injury and Liver Failure [see Warnings and Precautions (5.1)] Hypersensitivity Reactions, Including Anaphylaxis [see Warnings and Precautions (5.2)] Patients Who Discontinued or Interrupted Elexacaftor-, Tezacaftor-, or Ivacaftor-Containing Drugs Due to Adverse Reactions [see Warnings and Precautions (5.3)] Intracranial Hypertension …» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Qué interacciones tiene Vanzacaftor, tezacaftor, and deutivacaftor?
La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Alyftrek, Vertex Pharmaceuticals Incorporated, 26 de agosto de 2026) comienza así, en inglés: «Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5.6, 7.1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2.3, 5.7, 7.1) 7.1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Vanzacaftor, tezacaftor, and deutivacaftor tiene una advertencia en recuadro?
Sí. La etiqueta de la FDA de Alyftrek tiene una advertencia en recuadro («WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE»), la advertencia más seria de la FDA. Léala en la etiqueta completa y pregunte a su farmacéutico.
¿Hay escasez de Vanzacaftor, tezacaftor, and deutivacaftor?
La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
¿Se ha retirado del mercado Vanzacaftor, tezacaftor, and deutivacaftor?
No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
¿Quién fabrica Vanzacaftor, tezacaftor, and deutivacaftor?
1 empresa tiene productos con receta de Vanzacaftor, tezacaftor, and deutivacaftor en el directorio NDC de la FDA, entre ellas Vertex Pharmaceuticals Incorporated.

Para qué se usa Vanzacaftor, tezacaftor, and deutivacaftor

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 5 ) or results in production of CFTR protein […]. …

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (tablet, film coated, oral), Alyftrek, Vertex Pharmaceuticals Incorporated; abarca 2 productos del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Su título: WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE. Leerla en la etiqueta completa →

Vanzacaftor, tezacaftor, and deutivacaftor: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients who were taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as ALYFTREK.

Leer más de esta sección

Liver injury has been reported within the first month of therapy and up to 15 months following initiation of elexacaftor/tezacaftor/ivacaftor [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK, every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or elevated liver function tests at baseline [see Dosage and Administration (2.1), Warnings and Precautions (5.1), Adverse Reactions (6), and Use in Specific Populations (8.7)]. Interrupt ALYFTREK for significant elevations in liver function tests or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve, resume treatment only if the benefit is expected to outweigh the risk. Closer monitoring is advised after resuming ALYFTREK [see Warnings and Precautions (5.1)]. ALYFTREK should not be used in patients with severe hepatic impairment (Child-Pugh Class C). ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and the benefit outweighs the risk. If used, monitor patients closely [see Dosage and Administration (2.4), Warnings and Precautions (5.1), Adverse Reactions (6), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)]. WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE See full prescribing information for complete boxed warning. Elevated transaminases have been observed in patients treated with ALYFTREK (5.1, 6). Cases of serious and potentially fatal drug-induced liver injury and liver failure leading to transplantation and death were reported in patients who were taking ELX/TEZ/IVA, a drug containing the same or similar active ingredients as ALYFTREK (5.1). Assess liver function tests (ALT, AST, alkaline phosphatase, bilirubin) in all patients prior to initiating ALYFTREK, every month for first 6 months, every 3 months for next 12 months, then at least annually (2.1, 5.1). Interrupt ALYFTREK for significant elevations in LFTs or signs or symptoms of liver injury. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve (5.1). Resume ALYFTREK if abnormalities resolve and only if the benefit is expected to outweigh the risk (5.1). ALYFTREK should not be used in patients with severe hepatic impairment (Child-Pugh Class C).

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Vanzacaftor, tezacaftor, and deutivacaftor

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Drug-Induced Liver Injury and Liver Failure [see Warnings and Precautions (5.1)] Hypersensitivity Reactions, Including Anaphylaxis [see Warnings and Precautions (5.2)] Patients Who Discontinued or Interrupted Elexacaftor-, Tezacaftor-, or Ivacaftor-Containing Drugs Due to Adverse Reactions [see Warnings and Precautions (5.3)] Intracranial Hypertension …

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Interacciones de Vanzacaftor, tezacaftor, and deutivacaftor

Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.

Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5.6, 7.1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2.3, 5.7, 7.1) 7.1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A.

Leer más de esta sección

Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure [see Clinical Pharmacology (12.3)] which may reduce ALYFTREK effectiveness [see Warnings and Precautions (5.6)]. Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor [see Dosage and Administration (2.3)]. Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a strong CYP3A inhibitor increases vanzacaftor, tezacaftor, and deutivacaftor exposure [see Clinical Pharmacology (12.3)], which may increase the risk of ALYFTREK adverse reactions [see Warnings and Precautions (5.7)]. Concomitant use with a moderate CYP3A inhibitor is predicted to increase vanzacaftor, tezacaftor, and deutivacaftor exposure [see Clinical Pharmacology (12.3)], which may increase the risk of ALYFTREK adverse reactions [see Warnings and Precautions (5.7)]. Grapefruit Food or drink containing grapefruit should be avoided during treatment with ALYFTREK. Concomitant use of ALYFTREK with grapefruit juice which contains one or more components that moderately inhibit CYP3A may increase exposure of vanzacaftor, tezacaftor and deutivacaftor. 7.2 Effect of ALYFTREK on Other Drugs P-glycoprotein (P-gp) Substrates Unless otherwise recommended in the P-gp substrate Prescribing Information, monitor more frequently for adverse reactions with concomitant use of ALYFTREK with P-gp substrates where minimal concentration changes may lead to serious adverse reactions related to P-gp substrates. Tezacaftor and deutivacaftor (components of ALYFTREK) are P-gp inhibitors. Administration of tezacaftor/ivacaftor increases exposure of P-gp substrates [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates. Breast Cancer Resistance Protein (BCRP) Substrates Unless otherwise recommended in the BCRP substrate Prescribing Information, monitor more frequently for adverse reactions with concomitant use of ALYFTREK with BCRP substrates where minimal concentration changes may lead to serious adverse reactions related to BCRP substrates. Vanzacaftor (VNZ) and deutivacaftor (D-IVA) (components of ALYFTREK) are inhibitors of BCRP in vitro. Concomitant use of ALYFTREK with BCRP substrates may increase exposure of these substrates; however, this has not been studied clinically [see Clinical Pharmacology (12.3)]. CYP2C9 Substrates Use caution when ALYFTREK is used concomitantly with CYP2C9 substrates. Monitor the international normalized ratio (INR) more frequently with concomitant use of ALYFTREK with warfarin.

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Dosis de Vanzacaftor, tezacaftor, and deutivacaftor

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

Prior to initiating ALYFTREK obtain liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients. Monitor liver function tests every month during the first 6 months of treatment, then every 3 months during the next 12 months, then at least annually thereafter.

Leer más de esta sección

(2.1, 5.1) Recommended Dosage for Adult and Pediatric Patients Aged 6 Years and Older (with fat-containing food) (2.2) Age Weight Once Daily Oral Dosage 6 to less than 12 years old Less than 40 kg Three tablets of vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg Greater than or equal to 40 kg Two tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg 12 years and older Any Weight Two tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg Should not be used in patients with severe hepatic impairment. Use not recommended in patients with moderate hepatic impairment unless the benefit outweighs the risk. If used, no dose adjustment is recommended. Liver function tests should be closely monitored. (2.4, 5.1, 6.1, 8.7) See full prescribing information for dosage modifications for concomitant use of ALYFTREK with strong or moderate CYP3A inhibitors. (2.3, 5.7, 7.1) 2.1 Recommended Laboratory Testing Prior to ALYFTREK Initiation and During Treatment Prior to initiating ALYFTREK, obtain liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) for all patients. Monitor liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease, elevated liver function tests at baseline, or a history of elevated liver function tests with drugs containing elexacaftor, tezacaftor, and/or ivacaftor [see Warnings and Precautions (5.1) and Use in Specific Populations (8.7)]. 2.2 Recommended Dosage The recommended ALYFTREK dosage in adult and pediatric patients aged 6 years and older is provided in Table 1. Administer ALYFTREK orally (swallow the tablets whole) with fat-containing food, once daily, at approximately the same time each day [see Clinical Pharmacology (12.3)]. Examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs, peanut butter, cheeses, nuts, whole milk, or meats.

Tabla de la etiqueta
AgeWeightOnce Daily Oral Dosage
6 to less than 12 years oldLess than 40 kgThree tablets of vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg
Greater than or equal to 40 kgTwo tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg
12 years and olderAny WeightTwo tablets of vanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Vanzacaftor, tezacaftor, and deutivacaftor en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Risk Summary There are no available data on ALYFTREK use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Although there are no animal reproduction studies with the concomitant administration of vanzacaftor, tezacaftor, and deutivacaftor, separate reproductive and developmental studies were conducted with vanzacaftor and tezacaftor in pregnant rats and rabbits.

Leer más de esta sección

Deutivacaftor is a deuterated isotopologue of ivacaftor with a toxicity profile similar to ivacaftor. Reproductive and development studies were conducted with ivacaftor in pregnant rats and rabbits. In animal embryo fetal development (EFD) studies, oral administration of vanzacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 30 times the exposure at the maximum recommended human dose (MRHD) in rats and 22 times the MRHD in rabbits. Oral administration of tezacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 3 times the exposure at the MRHD in rats and 0.2 times the MRHD in rabbits (based on summed AUCs of tezacaftor and the metabolite M1-TEZ). Oral administration of ivacaftor to pregnant rats and rabbits during organogenesis demonstrated no adverse developmental effects at doses that produced maternal exposures up to approximately 8 and 9 times the exposure at the MRHD, respectively (based on AUC of ivacaftor for rats and rabbits). No adverse developmental effects were observed after oral administration of vanzacaftor, tezacaftor, or ivacaftor to pregnant rats from the period of organogenesis through lactation at doses that produced maternal exposures approximately 18 times, 1 time, and 8 times the exposures at the MRHD, respectively (based on AUCs of vanzacaftor, tezacaftor and M1-TEZ, and ivacaftor) (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Vanzacaftor: In an EFD study, pregnant rats were administered vanzacaftor at oral doses of 2.5, 5, and 10 mg/kg/day during the period of organogenesis from gestation Days 6-17. Vanzacaftor did not cause adverse effects to the fetus at exposures up to 30 times the MRHD (based on AUC for vanzacaftor at maternal doses up to 10 mg/kg/day). In an EFD study, pregnant rabbits were administered vanzacaftor at oral doses of 10, 40, and 70 mg/kg/day during the period of organogenesis from gestation Days 7-20. Vanzacaftor did not cause adverse effects to the fetus at exposures up to 22 times the MRHD (based on AUC of vanzacaftor at maternal doses up to 40 mg/kg/day).

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Sobredosis de Vanzacaftor, tezacaftor, and deutivacaftor

Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).

Treatment of overdosage consists of general supportive measures including monitoring of vital signs and observation of the clinical status.

— Etiqueta de la FDA: Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Formas farmacéuticasTableta, recubierta con película
VíaOral
Productos con receta2 en el directorio NDC de la FDA
Nombres de marcaAlyftrek

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

Historial de aprobación de la FDA

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
Solicitudes de marca y biológicas
SolicitudPatrocinadorAprobadaCambios aprobados después
NDA218730
ALYFTREK
Vertex Pharms Inc20 de diciembre de 2024 3, el último 27 de marzo de 2026
2026: Eficacia · 2026: Etiquetado · 2025: Etiquetado

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

RxCUI (RxNorm)2701438, 2701444, 2701448, 2701450
ID (SPL set ID) de la etiqueta citada7e635909-c6fd-4f0d-ae77-cdff03653a20
Etiquetas de la FDA (SPL)1
Solicitudes de la FDANDA218730
Principios activos (FDA)DEUTIVACAFTOR / TEZACAFTOR / VANZACAFTOR

Siguientes pasos

Fuentes

  1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Alyftrek, Vertex Pharmaceuticals Incorporated, vigente desde el 26 de agosto de 2026; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
  5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos